All EMA articles
-
BusinessPharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
ResearchInsulin medicines more resilient to temperature than previously thought
Review suggests more lenient storage guidelines could make diabetes treatments more accessible
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
OpinionWhen regulatory cooperation goes too far, we all lose
Were FDA staff unduly influenced by Biogen in approving Alzheimer’s antibody?
-
BusinessBudget cuts at UK medicines regulator raise eyebrows
MHRA to cut 300 jobs amid financial pressures arising from Brexit
-
BusinessSartan contaminant recall hits generics manufacturers
Three European suppliers recalling multiple batches of medicines owing to active ingredient contamination
-
BusinessUK grants Pfizer–BioNTech Covid-19 vaccine emergency approval
Regulators around the world working towards accelerated decisions on vaccine data
-
OpinionHopes and fears for remdesivir
Available resources for testing coronavirus treatments need to be used wisely
-
BusinessCancer and rare diseases dominated 2019 drug approvals
More streamlined review processes and changing R&D priorities have contributed to sustained increase in new medicines
-
BusinessResearchers call for stricter rules on drug-like medical devices
More oversight is needed over products in the grey area between medical device and medication
-
BusinessNitrosamine contamination withdrawals spread to new drugs
After ranitidine recalls, EU regulators instruct companies to review all their products for potential impurities
-
OpinionWill Novartis's data manipulation damage relations with regulators?
Trust between the two has been compromised
-
NewsData manipulation casts shadows on Novartis gene therapy
Manufacturing problems with other new medicines highlight difficulty of developing advanced treatments
-
BusinessWhat might Brexit mean for industry?
Questions hang over regulation, trade, talent and investment
-
BusinessPharmaceuticals roundup 2018
Merger deals, product approvals and infrastructure changes have been overshadowed by political uncertainty, in Europe and around the world
-
BusinessEurope opens gates to CAR-T
First two modified T-Cell cancer therapies approved in the EU, but prices may be prohibitive for public health systems
-
CareersLife in Amsterdam
The capital of the Netherlands has a thriving chemical community, if you’re allowed to work there
-
BusinessPharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
-
BusinessEuropean drug regulator heads to Amsterdam
Brexit drives EMA to relocate, taking hundreds of jobs and significant expertise away from UK
-
NewsUK's post-Brexit wish list of scientific collaborations published
Government wants the country to remain part of Horizon 2020 research programme and continue nuclear, space and defence associations